Where Life Sciences Leadership Is Heading in 2027

European life sciences is entering a new phase. After two years in which many organisations prioritised cost discipline, portfolio focus, and operational resilience, the market is shifting toward execution: advancing late-stage programmes, scaling manufacturing, preparing for AI-related regulatory expectations, and rebuilding leadership capability where it was reduced during the downturn.

That shift is changing what organisations need from senior talent. The most sought-after leaders are no longer defined only by functional expertise or past title. They are being selected for their ability to own a defined mandate, make decisions under uncertainty, integrate cross-functional teams, and deliver through the next stage of growth.

The patterns visible across 2026 point to a more competitive, more selective, and more cross-sector market heading into 2027. Demand is strengthening for regulatory and AI-governance leadership, technical operations and manufacturing expertise, and executives able to lead organisations through portfolio change. At the same time, the pool of experienced leaders with recent, directly relevant operating experience remains constrained.

This report examines where senior movement is concentrated, why certain functions have become harder to hire for, how the relationship between pharma, biotech, and medtech is evolving, and what these patterns signal for the year ahead.

The defining change in European life sciences is not simply that hiring has returned. It is that the purpose of hiring has changed.

During 2024 and 2025, many organisations focused on extending runway, narrowing portfolios, reducing fixed cost, and protecting core programmes. That environment naturally reduced the number of senior appointments and encouraged experienced leaders to remain in larger organisations, move into advisory or fractional work, or wait for clearer signs of stability.

In 2026, the emphasis has moved toward delivery. Companies are advancing clinical programmes, preparing assets for regulatory milestones, integrating acquisitions, building manufacturing capability, and responding to the growing governance requirements associated with AI and data-intensive development.

This creates a specific talent problem. Organisations that reduced leadership depth during the downturn now need experienced operators, but many of those leaders have already moved, changed the shape of their careers, or become more selective about the mandates they will accept.

The result is a market where demand for proven senior talent is strengthening, while supply remains tight. The most competitive organisations are not simply those with the strongest funding position. They are those able to offer a credible mandate, meaningful authority, and a realistic path to impact.

Regulatory affairs combined with AI governance is the standout area, followed closely by technical operations and manufacturing leadership.

The demand is driven by a regulatory and operational shift rather than a general hiring recovery. In January 2026, EMA and the FDA published ten joint guiding principles for AI across the medicines lifecycle, increasing the need for leaders who can connect regulatory strategy, data governance, model validation, and quality systems.

Lundbeck’s March 2026 appointment of Markus Kede as SVP and Chief AI Officer illustrates the emerging profile: a senior leader responsible for embedding AI into core workflows, governance, and decision-making, not simply overseeing technology projects.

The scarcest 2027 profiles will combine EU and US regulatory strategy, AI/ML validation and data governance, GxP and quality-system experience, and the credibility to lead cross-functional governance without slowing innovation.

This is not simply a technology hiring trend. It is a governance trend. Organisations need leaders who can determine where AI creates value, where it introduces regulatory or quality risk, how decisions are documented, and how accountability is maintained across research, clinical development, manufacturing, and pharmacovigilance.

For regulatory leaders, the career implication is significant. Experience in traditional submissions and regulatory strategy remains essential, but it is no longer sufficient on its own. The premium is moving toward leaders who can operate confidently at the intersection of regulation, data, digital systems, and organisational change.

Because companies are moving from financing and transactions into integration, scale-up, and supply readiness.

Ipsen appointed Pierrick Lefranc as EVP Technical Operations, effective April 2026, reflecting the rising strategic weight of manufacturing, supply, and operational execution.

The most contested profiles are not broad manufacturing generalists. They are CMC strategy leaders, MSAT and technology-transfer specialists, and process-development leaders with experience across development and GMP environments. Demand is strongest where organisations are integrating acquired assets, preparing pivotal-stage manufacturing, or building commercial-scale supply chains.

The difficulty is that these capabilities rarely sit in one person. A leader may understand process development but have limited experience managing comparability through regulatory review. Another may have strong GMP operations experience but less exposure to early-stage process design or technology transfer. A third may have deep modality expertise but limited experience operating at commercial scale.

That mismatch between what organisations need and what the market can supply is what makes technical operations one of the most active areas for senior search. It is also why hiring timelines in this function are likely to remain extended: organisations are not only competing for available leaders, but often need to build hybrid capability across several appointments.

Heading into 2027, the strongest demand will be for leaders who can connect scientific development, manufacturing strategy, quality, regulatory expectations, and supply continuity. In advanced therapies, biologics, and complex modalities, those leaders are particularly scarce because small differences in process decisions can have major consequences for scalability, comparability, and regulatory outcomes.

It has become more selective and mandate-led.

Senior leaders are still moving from large pharma into biotech, but the strongest moves are driven by defined ownership: a late-stage asset, a clear regulatory path, meaningful decision rights, and a credible operating environment—not equity upside alone.

Ipsen appointed Michelle Werner as EVP and President, North America in March 2026. She joined from Alltrna, where she had been President and CEO, after serving as CEO-Partner at Flagship Pioneering.

For candidates, the implication is that compelling opportunities are becoming more specific. Broad transformation mandates are less persuasive than clearly scoped roles with authority over a programme, function, or market.

The earlier phase of pharma-to-biotech movement was often associated with the appeal of innovation, equity upside, and proximity to emerging science. That dynamic has not disappeared, but it has become more disciplined. Senior leaders are asking harder questions about cash position, board alignment, pipeline quality, regulatory strategy, and the realistic probability of reaching the next value-creation milestone.

The reverse flow is equally important. Established pharma companies continue to attract experienced biotech operators who bring speed, programme ownership, external-facing credibility, and comfort operating in resource-constrained environments. The movement is therefore bidirectional, but in both directions it is increasingly driven by fit and mandate rather than title alone.

For employers, this means that senior candidates are evaluating opportunities more like investors. They want to understand the asset, the evidence package, the decision-making culture, the authority attached to the role, and the organisation’s ability to support delivery.

Portfolio reshaping, ownership change, and strategic refocus.

Medtech movement in 2026 has been shaped less by pipeline acceleration and more by companies restructuring around higher-growth priorities. Teleflex appointed Jason Weidman, a longtime Medtronic executive, as President and CEO effective June 2026, as it reshaped its portfolio through divestitures. Hologic appointed former Baxter CEO José Almeida as CEO in April 2026, alongside completion of its take-private transaction.

These are portfolio-navigation appointments rather than conventional operational hires. The leaders being selected are those with experience steering organisations through divestiture, integration, private ownership, strategic refocus, and the operational consequences of a narrower growth agenda.

That has a direct effect on the wider medtech talent market. When a company reshapes its portfolio, it creates movement not only at CEO level but also across finance, strategy, regulatory affairs, quality, commercial leadership, and business-unit management. Leaders who have operated through structural change become especially valuable because they understand how to maintain performance while redesigning the organisation around it.

Below the CEO level, demand is concentrated in EU MDR and AI-related regulatory leadership, quality and post-market surveillance, and commercial roles across diagnostics, digital health, connected care, and bioelectronics.

The most attractive medtech profiles increasingly sit across boundaries. Regulatory leaders need to understand both device regulation and software or AI-related obligations. Commercial leaders need to understand clinical environments, procurement dynamics, digital adoption, and the evidence requirements that support reimbursement. Quality leaders need to operate across hardware, software, data, and post-market vigilance.

For candidates, this creates an opportunity: leaders who can translate between medtech, digital health, and regulated healthcare environments are becoming more valuable than those with a single-sector background.

Between traditional life sciences and AI, digital-health, diagnostics, and technology-enabled service businesses.

Pharma and biotech are no longer competing only with each other for senior regulatory, medical-affairs, commercial, and data leadership. AI platforms, digital-health companies, CROs, and technology-enabled providers are building leadership teams that need people who can operate credibly in regulated life-sciences environments.

This is one of the most important changes in the market because it expands the definition of competition. A pharma company hiring a senior regulatory leader may now be competing not only with another pharmaceutical company or biotech, but also with a technology company building life-sciences products, a diagnostics business scaling its evidence strategy, or a digital-health organisation entering regulated clinical workflows.

The appeal of these organisations is not only compensation. It can include broader technology exposure, faster decision cycles, a more visible connection between leadership decisions and product outcomes, and the opportunity to build something at the intersection of healthcare, data, and software.

For employers in traditional life sciences, this creates a retention challenge. Senior regulatory, medical-affairs, commercial, and data leaders may receive credible approaches from organisations outside the sector. Retention strategies therefore need to address more than salary progression. They must also offer scope, autonomy, strategic influence, access to decision-makers, and a credible narrative about the organisation’s future.

For candidates, the opportunity is to become deliberately cross-sector. The most portable profiles are those that combine deep life-sciences credibility with fluency in technology, data, digital products, or commercial transformation.

The market will reward leaders who can execute, not only those who can strategy-plan.Expect continued competition for regulatory and AI-governance leadership, CMC and manufacturing-scale talent, and experienced CMOs with late-stage accountability and credible regulator engagement. Cross-sector competition from AI and digital-health organisations should also intensify.The organisations most likely to succeed in senior hiring will be those that can answer four questions clearly:

• What is the leader being asked to own?
• What decisions can they make without unnecessary escalation?
• What resources, team, and governance structure will support delivery?
• Why is this mandate important to the organisation’s next phase?

For employers, the priority is retention: offer real ownership, clear decision rights, credible transformation mandates, and compensation structures that reflect the widening market for senior talent.For candidates, the strongest positions will be those with a defined mandate, visible impact, and a credible path through the next phase of execution. The leaders who move most successfully in 2027 are likely to be those who choose specificity over breadth: a clear programme, a clear operating environment, and a clear opportunity to shape outcomes.

Whether you are considering your next move or simply want a clearer view of the market, understanding where senior talent is moving is valuable before you need it.
Start a conversation with our Life Sciences team.